FDA：否决维D“减少多发性硬化症风险”声称
声称申请。
据了解，本次健康声称申请的内容为“摄取维生素D可减少多发性硬化症发生的风险”，由Burdock Group代表拜耳公司提出。多发性硬化症是一种可损害人体中枢神经系统的慢性自身免疫性疾病。
美国FDA对申请材料进行评估认为，没有可靠的证据表明摄入维生素D会降低多发性硬化症的风险。
部分原文报道如下——
The U.S. Food and Drug Administration today denied a request for use of a qualified health claim that consumption of vitamin D may reduce the risk of developing multiple sclerosis (MS), a chronic autoimmune disorder that damages the body's central nervous system.
The FDA thoroughly reviewed the 85 publications submitted by the Burdock Group on behalf of Bayer, as well as all the publications cited in the petition's appendix. The agency also conducted a vast independent literature review of hundreds of additional publications. Through this rigorous assessment, the FDA determined that scientific conclusions could not be drawn about the relationship between vitamin D intake and MS risk. based on the agency's review of the totality of publicly available scientific evidence, the FDA has concluded that there is no credible evidence of a relationship between intake of vitamin D and a reduced risk of MS.